Macro and Microeconomic Factors Continue to Impact Borderline Personality Disorder Market During 2017 - 2025

Borderline personality disorder (BPD), also known as cluster-B personality disorder, is a neurological health disorder. BPD affects the way a person feels and thinks about oneself and others. Common signs and symptoms of the disorder may include fear of abandonment, self-injuries such as suicidal tendency, intense anger, irritability, dangerous behavior, mood swings, identity disturbance, and chronic feelings of emptiness. Currently, there is no single cause of this disorder. BPD can be caused by a combination of factors such as genes and brain compounds or neurotransmitters. Neurotransmitters are brain chemical messengers that transmit essential information throughout the brain and body.

Report Overview and TOC @ https://www.transparencymarketresearch.com/borderline-personality-disorder-market.html

Neurological factors such as estrogen can lead to BPD. Varying estrogen cycles in women make them susceptible to the disorder. Self-injury, depression, and bipolar disorder are major complications of BPD. Borderline personality disorder is diagnosed by a mental health professional through the subject’s history, statistical manual, and procedures. Magnetic resonance imaging (MRI) is a test that uses for borderline personality disorder. Currently, there is no cure for borderline personality disorder; however, a few marketed drugs (antidepressants, mood stabilizers, and antipsychotics) are expected to help improve the symptoms of the disorder. Increasing prevalence of BPD across the globe is expected to drive the global borderline personality disorder market. Additionally, growing global awareness fuels the growth of the market. Multifactorial etiology and complex pathophysiology of the disorder are likely to be major restraints of the market.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30647

The global borderline personality disorder market can be segmented based on treatment, end-user, and region. In terms of treatment, the market can be categorized into psychotherapy and drugs. BPD is primarily treated with psychotherapy. Psychotherapy is also called talk therapy, which is the fundamental treatment approach for this disorder. The primary focus of psychotherapy is to restore the current ability to function, manage emotions, and improve relationships. Psychotherapy can be segmented into dialectical behavior therapy (DBT), mentalization-based therapy (MBT), schema-focused therapy, and transference-focused therapy (TFP) and others. There is no approved drug for BPD; however, certain drugs could help reduce symptoms or co-occurring problems such as anxiety and depression. Drugs could include antipsychotics or mood-stabilizing and antidepressants. In terms of end-user, the borderline personality disorder market can be segmented into psychiatric hospital and home health care. In terms of revenue, the psychiatric hospital segment held a significant share of the market in 2016.

For Specific and Customized requirements @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=30647

In terms of region, the global borderline personality disorder market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for the largest share of the global borderline personality disorder market in 2016, followed by Europe and Asia Pacific. The U.S. held a major share of the market in North America in terms of revenue. The market in Asia Pacific is expanding rapidly due to increase in number of patients. However, Asia Pacific is projected to be the most attractive market in the near future, especially emerging economies such as India, China, and Japan due to its better health care infrastructure, economic growth, increasing number of insurance payer, expanding and developing private health care sector, and increasing awareness among people.

Key players in the global borderline personality disorder market include Bristol-Myers Squibb, AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, and Pfizer Inc.

Pre Book full report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=30647<ype=S

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. 

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

This release was published on openPR.